vv-ecmo for ards after eolia… · 2019. 11. 22. · •prone position, hfo ventilation, almitrine...

La Pitié Salpêtrière Paris www.paris-ecostcs.com [email protected]

VV-ECMO for ARDS after EOLIA…Alain Combes, MD, PhD

Cardiology Institute, Hôpital Pitié-Salpêtrière, AP-HP

Inserm UMRS 1166, iCAN, Institute of Cardiometabolism and Nutrition

Sorbonne Université, Paris, [email protected]

mailto:[email protected]


Disclosures• Principal Investigator: EOLIA trial

• VV ECMO in ARDS• NCT01470703 • Partly sponsored by MAQUET, Getinge Group

• Received honoraria for lectures and consulting from • MAQUET, BAXTER, XENIOS



The rationale ofhigh flow VV-ECMO…To completely replace pulmonary functionIn patients dying of refractory hypoxemia… ORFor whom MV becomes dangerous…



Influenza A H1N1 induced ARDS



The rationale ofhigh flow VV-ECMO…To decrease the intensity of MV to protect the lungs

To allow the lungs to rest…To allow healing of the lungs…



Potential Physiologic Mechanisms of Benefit of ECLS for Respiratory Failure



Why early ECMO?To rapidly decrease the intensity of MV



0

0.2

0.4

0.6

0.8

1

0 20 40 60 80 100 120 140 160 180

MV 3-10 days before ECMO

MV >10 days before ECMO

P <0.005, log-rank

MV <3 days before ECMO



10

15

20

25

30

20

25

30

35

40

0

100

200

300

400

500Before ECMO After ECMO

0 0

Driving Pressure Tidal Volume Plateau Pressure



Mechanical Power Concept• Energy transferred to the lungs/alveoli

• Components• Tidal volume (TV)/driving pressure (ΔPaw)

• Flow

• Positive end-expiratory pressure (PEEP)

• Respiratory rate (RR)



Serpa Neto et al, Intensive Care Medicine, 2018



Mechanical Power, J/min

LifeGuard, A Cohort of 350 patients on VV-ECMOSchmidt et al, AJRCCM 19



VV-ECMO indicationsafter EOLIA…



Trial Procedures



Trial proceduresECMO Group• Percutaneous VV Cannulation

• Low anticoag. with Heparin• aPTT 40–55 seconds

• MV settings• VAC

• PEEP ≥10, VT set for Pplat ≤24 cmH2O

• Pressure controlled/APRV• PLow ≥10; PHigh ≤24 cmH2O; I:E, 1/2

• FIO2 30-50%, RR 10–30

Control Group• MV settings

• Express trial; High recruitment arm • VT at 6 ml/kg• PEEP to reach Pplat 28–30 cm H2O

• Strong recommendation for• Prolonged periods of prone position• Paralyzing agents

• In case of hypoxemia• Recruitment maneuvers • iNO, inhaled prostacyclin



Rescue ECMO for Controls• Refractory hypoxemia

• SaO2 <80% for >6 hours

• Despite mandatory trial of• Prone positioning AND

• Recruitment maneuver AND

• iNO or inhaled prostacyclin

• AND If the treating physician felt that• Patient had no irreversible multi-organ failure AND

• ECMO might change the outcome



Primary Endpoint



Hazard Ratio, 0.70; 95% CI, 0.47-1.04, P=0.074 by log-rank test

0

5

10

15

20

25

30

35

40

45

50

ECMO Control

35 46

Perc

ent

D6

0 M

ort

alit

yPrimary EndpointRelative Risk, 0.76, 95% Cl, 0.55-1.04; P=0.087



Key Secondary EndpointDeath in ECMO group patients

Death or Crossover to ECMO in controls



Hazard ratio, 0.48; 95% CI, 0.34-0.70, P <0.001 by log-rank test

0

10

20

30

40

50

60

ECMO Control

35

57

Perc

ent

D6

0 T

reat

men

tFa

ilure

Key Secondary EndpointRelative Risk, 0.62; 95% CI, 0.47-0.82; P<0.001

Death in ECMO group patients; Death or Crossover to ECMO in control patientsPe

rcen

t D

60

Tre

atm

ent

Failu

re



Crossover to ECMO



Crossover to ECMO in Controls• 28% (35/125) of controls received rescue ECMO

• Refractory hypoxemia, 6.5±9.7 days postrandomization

• These patients had more severe ARDS at baseline• Higher Plateau pressure:

• 31.7±5.5 vs 28.5±4.1 cm H2O

• Higher Driving pressure: • 20.2±6.1 vs 16.6±5.3 cm H2O

• Lower Respiratory system compliance: • 21.3±9.2 vs 27.1±11.0 ml/cm H2O

• More quadrants with infiltrate on chest Xray: • 3.7±0.6 vs 3.3±0.9



H-24-18 H-18-12 H-12-6 H-6-3 H-3-0 H-24-18 H-18-12 H-12-6 H-6-3 H-3-0

H-24-18 H-18-12 H-12-6 H-6-3 H-3-0 H-24-18 H-18-12 H-12-6 H-6-3 H-3-0

Inotropic Score, P < 0.001 Pao2, P < 0.001

Arterial lactate, P < 0.001 Pao2:Fio2, P < 0.001



Crossover to ECMO in Controls• Before crossover, of the 35 controls who had ECMO

• 9 had cardiac arrest

• 7 had severe right heart failure

• 11 developed renal failure requiring dialysis

• Venoarterial ECMO applied to 7 patients• 6 under cardiopulmonary resuscitation



0

10

20

30

40

50

60

ECMO No Crossover All Controls Crossover

3541

4657

Perc

en

t M

ort

alit

y

Control Crossover Outcomes



Matching weight ponderation:Rescue ECMO (35) vs. First line ECMOSimilar baseline severity

Mortality: Rescue ECMO 57% vs. First line ECMO 35%Hazard ratio, 1,64; 95% CI, 1,08-2.49

P = 0.02



Subgroups…



Which patients should receive ECMO?



Inclusion Criteria• One of the 3 following disease severity criteria

• PaO2:FIO2 <50 mmHg for >3 hours• Despite potential use of inhaled NO, recruitment maneuvers

• Prone position, HFO ventilation, almitrine infusion

• PaO2:FIO2 <80 mmHg for >6 hours• Despite similar criteria as above

• pH <7.25 with PaCO2 >60 mmHg for >6 hours • Resulting from MV settings to keep Pplat ≤32 cm H2O

• Despite respiratory rate increased to 35/minute



Endpoint

ECMO group

(N = 124)

Control group

(N = 125)

Absolute Risk

Difference or Median

Difference (95% CI)

Day 60 mortality by inclusion criteria

Criteria #1 — no. died/ total no. (%) 1/5 (20) 1/11 (9) 10.9 (-25.0 to 56.9)

Criteria #2 — no. died/ total no. (%) 37/94 (39) 45/94 (48) -8.5 (-22.4 to 5.7)

Criteria #3 — no. died/ total no. (%) 6/25 (24) 11/20 (55) -31.0 (-55.7 to -2.2)



Bayesian Model



JAMA. October 22, 2018, doi:10.1001/jama.2018.14276



Bayesian Analysis of EOLIA…



Bayesian Analysis of EOLIA…Dead space and static compliance determine the effect of ECCO2R

on driving pressure and mechanical power

Posterior Probability of Positive Effect of ECMO in

Severe ARDS Patients88% to 99%



Clinicians and researchers should no longer ask

“Does ECMO work?” because that question appears to be

answered...

Instead, the key question that should now be asked is “By

how much does ECMO work, in whom, and at what cost?”



And now the Meta-Analyses…



Lancet Resp Med, 2019



Conclusions• ECMO does not kill people!• ECMO is very likely of benefit to patients with severe ARDS

• All patients should receive Prone prior to ECMO• Unclear at present which patients will benefit the most

• Driving pressure? Mechanical Power?

• Further studies are needed:• Which patients• Optimal ventilatory strategy during ECMO

• +/- prone during ECMO• Optimal coagulation regimen• ECMO vs ECCO2R



www.paris-ecostcs.com


vv-ecmo for ards after eolia… · 2019. 11. 22. · •prone position, hfo ventilation, almitrine...

Documents